Replies to post #18102 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA 2018 News Flow

[Miscellaneous updates.]


Proprietary autoimmune program

• 1H18: Start phase-1 trial of M230, which is partnered with CSL (#msg-127656306).

• 2018: Report full dataset from M281 phase-1 trial at an unspecified medical conference. (Top-line data were reported in Jan 2018: #msg-137491062.)

• 2018 Start phase-1 trial of M254, a hyper-sialylated IVIG.


FoB program

• Timing unknown: M923 (Humira FoB) partnership or divestiture.

• 1H18: Start phase-3 trial for M710 (Eylea FoB).

• 2018: Report reason for inability of M834 (Orencia FoB) to meet its phase-1 pharmacokinetic endpoint; start phase-1 do-over, if necessary.